MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico.
Fair value with moderate growth potential.
Share Price & News
How has MEDNAX's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PDC's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PDC underperformed the German Healthcare industry which returned 1.9% over the past year.
Return vs Market: PDC underperformed the German Market which returned 2.5% over the past year.
Price Volatility Vs. Market
How volatile is MEDNAX's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is MEDNAX undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PDC (€15.3) is trading below our estimate of fair value (€31.33)
Significantly Below Fair Value: PDC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PDC is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.
PE vs Market: PDC is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PDC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PDC is good value based on its PB Ratio (1x) compared to the DE Healthcare industry average (1.4x).
How is MEDNAX forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PDC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: PDC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PDC's is expected to become profitable in the next 3 years.
Revenue vs Market: PDC's revenue is expected to decline over the next 3 years (-5% per year).
High Growth Revenue: PDC's revenue is forecast to decline over the next 3 years (-5% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PDC's Return on Equity is forecast to be low in 3 years time (13.7%).
How has MEDNAX performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PDC is currently unprofitable.
Growing Profit Margin: PDC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PDC is unprofitable, and losses have increased over the past 5 years at a rate of -51% per year.
Accelerating Growth: Unable to compare PDC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PDC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (9.7%).
Return on Equity
High ROE: PDC has a negative Return on Equity (-81.21%), as it is currently unprofitable.
How is MEDNAX's financial position?
Financial Position Analysis
Short Term Liabilities: PDC's short term assets ($940.9M) exceed its short term liabilities ($346.4M).
Long Term Liabilities: PDC's short term assets ($940.9M) do not cover its long term liabilities ($2.5B).
Debt to Equity History and Analysis
Debt Level: PDC's debt to equity ratio (141.3%) is considered high.
Reducing Debt: PDC's debt to equity ratio has increased from 42.7% to 141.3% over the past 5 years.
Debt Coverage: PDC's debt is not well covered by operating cash flow (12.8%).
Interest Coverage: PDC is unprofitable, therefore interest payments are not well covered by earnings.
What is MEDNAX current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PDC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PDC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PDC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PDC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PDC's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Roger Medel (73yo)
Dr. Roger J. Medel, M.D., Co-Founded at MEDNAX, Inc. (also known as Pediatrix Medical Group Inc.) in 1979. Dr. Medel served as the MEDNAX, Inc.’s President until May 2000 and as Chief Executive Officer unt ...
CEO Compensation Analysis
Compensation vs Market: Roger's total compensation ($USD8.07M) is above average for companies of similar size in the German market ($USD1.49M).
Compensation vs Earnings: Roger's compensation has been consistent with company performance over the past year.
|Executive VP & CFO||1.67yrs||US$3.40m||0.51% $6.7m|
|Senior VP & Chief Accounting Officer||4.17yrs||US$2.07m||0.13% $1.7m|
|Executive VP||8.17yrs||US$1.89m||0.13% $1.7m|
|Vice President of Strategy & Investor Relations||no data||no data||no data|
|Chief Compliance Officer & Operations Chief Legal Officer||1.5yrs||no data||no data|
|Chief Development Officer||6.58yrs||no data||no data|
|Chief Human Resources Officer||1.5yrs||no data||no data|
|Executive VP and Chief Strategy & Growth Officer||1.08yrs||no data||0.16% $2.1m|
|Chief Operating Officer of MEDNAX Radiology Solutions||no data||no data||no data|
Experienced Management: PDC's management team is considered experienced (2.9 years average tenure).
|Independent Director||17.67yrs||US$220.01k||0.029% $377.2k|
|Independent Chairman of the Board||16.17yrs||US$250.01k||0.058% $750.9k|
|Independent Director||16.17yrs||US$206.27k||0.045% $579.4k|
|Independent Director||24.75yrs||US$200.01k||0.72% $9.4m|
|Independent Director||21.08yrs||US$210.01k||0.038% $493.4k|
|Lead Independent Director||6.33yrs||US$235.01k||0.15% $1.9m|
|Independent Director||14.33yrs||US$203.74k||0.019% $241.1k|
|Independent Director||5.17yrs||US$200.01k||0.021% $275.8k|
|Independent Director||1.17yrs||US$245.42k||0.014% $187.1k|
Experienced Board: PDC's board of directors are seasoned and experienced ( 16.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
MEDNAX, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: MEDNAX, Inc.
- Ticker: PDC
- Exchange: DB
- Founded: 1979
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$1.467b
- Listing Market Cap: US$1.298b
- Shares outstanding: 83.69m
- Website: https://www.mednax.com
Number of Employees
- MEDNAX, Inc.
- 1301 Concord Terrace
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MD||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Sep 1995|
|PDC||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 1995|
|MD *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Sep 1995|
MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and their unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patients with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, pediatric ophthalmology, other newborn pediatric care, and newborn hearing screening program, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. Additionally, it offers consulting services to healthcare facilities and physicians. As of March 12, 2020, the company operated a network of approximately 4,325 physicians. MEDNAX, Inc. was founded in 1979 and is based in Sunrise, Florida.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/09 21:30|
|End of Day Share Price||2020/07/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.